Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology
Objective: To determine whether the apparent excess incidence of pneumothorax and pneumomediastinum in patients with coronavirus disease 2019 (COVID-19) is explained adequately by iatrogenic causes vs reflecting sequelae of severe acute respiratory syndrome coronavirus 2 infection. Patients and Meth...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-10-01
|
Series: | Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
Online Access: | http://www.sciencedirect.com/science/article/pii/S254245482100076X |
id |
doaj-834bda882b3a4bc087eb02eefe8e7040 |
---|---|
record_format |
Article |
spelling |
doaj-834bda882b3a4bc087eb02eefe8e70402021-08-26T04:35:39ZengElsevierMayo Clinic Proceedings: Innovations, Quality & Outcomes2542-45482021-10-0155827834Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic PathologyAayla K. Jamil, MBBS, MPH0Amit Alam, MD1Ronnie M. Youssef, MD2Joost Felius, PhD3Johanna S. van Zyl, PhD4Robert L. Gottlieb, MD, PhD5Baylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TXBaylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TX; Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TXCollege of Medicine, Texas A&M Health Science Center, Dallas, TXBaylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TXBaylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TXBaylor Scott & White Research Institute, Dallas, TX; College of Medicine, Texas A&M Health Science Center, Dallas, TX; Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, TX; Department of Internal Medicine, TCU and UNTHSC School of Medicine, Fort Worth, TX; Correspondence: Address to Robert L. Gottlieb, MD, PhD, Center for Advanced Heart and Lung Disease, Baylor Scott & White Health, 3410 Worth St, Suite 250, Dallas, TX 75246.Objective: To determine whether the apparent excess incidence of pneumothorax and pneumomediastinum in patients with coronavirus disease 2019 (COVID-19) is explained adequately by iatrogenic causes vs reflecting sequelae of severe acute respiratory syndrome coronavirus 2 infection. Patients and Methods: We retrospectively reviewed patients within our health care system from March 15, 2020, through May 31, 2020, who had a diagnosis of pneumothorax or pneumomediastinum during hospitalization for confirmed COVID-19 infection with attention to timing of pneumothorax and pneumomediastinum; presence, laterality, and placement, or attempts at central lines; and presence of mechanical ventilation before the event. Results: We report clinical data and outcomes from 9 hospitalized patients with COVID-19 who developed pneumothorax and/or pneumomediastinum among more than 1200 hospitalized patients admitted within our hospital system early in the pandemic. Many events were inexplicable by iatrogenic needle injury, including 1 spontaneous case without central line access or mechanical ventilation. One occurred before central line placement, 2 in patients with only a peripherally inserted central line, and 1 contralateral to a classic central line. Three of these 9 patients died of complications of COVID-19 during their hospital stay. Conclusion: With COVID-19 affecting the peripheral lung pneumocytes, patients are vulnerable to develop pneumothorax or pneumomediastinum irrespective of their central line access site. We hypothesize that COVID-19 hyperinflammation, coupled with the viral tropism that includes avid involvement of peripheral lung pneumocytes, induces a predisposition to peripheral bronchoalveolar communication and consequent viral hyperinflammatory-triggered pneumothorax and pneumomediastinum.http://www.sciencedirect.com/science/article/pii/S254245482100076X |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Aayla K. Jamil, MBBS, MPH Amit Alam, MD Ronnie M. Youssef, MD Joost Felius, PhD Johanna S. van Zyl, PhD Robert L. Gottlieb, MD, PhD |
spellingShingle |
Aayla K. Jamil, MBBS, MPH Amit Alam, MD Ronnie M. Youssef, MD Joost Felius, PhD Johanna S. van Zyl, PhD Robert L. Gottlieb, MD, PhD Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
author_facet |
Aayla K. Jamil, MBBS, MPH Amit Alam, MD Ronnie M. Youssef, MD Joost Felius, PhD Johanna S. van Zyl, PhD Robert L. Gottlieb, MD, PhD |
author_sort |
Aayla K. Jamil, MBBS, MPH |
title |
Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology |
title_short |
Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology |
title_full |
Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology |
title_fullStr |
Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology |
title_full_unstemmed |
Pneumothorax and Pneumomediastinum in COVID-19 Suggest a Pneumocystic Pathology |
title_sort |
pneumothorax and pneumomediastinum in covid-19 suggest a pneumocystic pathology |
publisher |
Elsevier |
series |
Mayo Clinic Proceedings: Innovations, Quality & Outcomes |
issn |
2542-4548 |
publishDate |
2021-10-01 |
description |
Objective: To determine whether the apparent excess incidence of pneumothorax and pneumomediastinum in patients with coronavirus disease 2019 (COVID-19) is explained adequately by iatrogenic causes vs reflecting sequelae of severe acute respiratory syndrome coronavirus 2 infection. Patients and Methods: We retrospectively reviewed patients within our health care system from March 15, 2020, through May 31, 2020, who had a diagnosis of pneumothorax or pneumomediastinum during hospitalization for confirmed COVID-19 infection with attention to timing of pneumothorax and pneumomediastinum; presence, laterality, and placement, or attempts at central lines; and presence of mechanical ventilation before the event. Results: We report clinical data and outcomes from 9 hospitalized patients with COVID-19 who developed pneumothorax and/or pneumomediastinum among more than 1200 hospitalized patients admitted within our hospital system early in the pandemic. Many events were inexplicable by iatrogenic needle injury, including 1 spontaneous case without central line access or mechanical ventilation. One occurred before central line placement, 2 in patients with only a peripherally inserted central line, and 1 contralateral to a classic central line. Three of these 9 patients died of complications of COVID-19 during their hospital stay. Conclusion: With COVID-19 affecting the peripheral lung pneumocytes, patients are vulnerable to develop pneumothorax or pneumomediastinum irrespective of their central line access site. We hypothesize that COVID-19 hyperinflammation, coupled with the viral tropism that includes avid involvement of peripheral lung pneumocytes, induces a predisposition to peripheral bronchoalveolar communication and consequent viral hyperinflammatory-triggered pneumothorax and pneumomediastinum. |
url |
http://www.sciencedirect.com/science/article/pii/S254245482100076X |
work_keys_str_mv |
AT aaylakjamilmbbsmph pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology AT amitalammd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology AT ronniemyoussefmd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology AT joostfeliusphd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology AT johannasvanzylphd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology AT robertlgottliebmdphd pneumothoraxandpneumomediastinumincovid19suggestapneumocysticpathology |
_version_ |
1721196007545372672 |